1. Home
  2. KRC vs ACAD Comparison

KRC vs ACAD Comparison

Compare KRC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kilroy Realty Corporation

KRC

Kilroy Realty Corporation

HOLD

Current Price

$37.38

Market Cap

4.5B

Sector

Real Estate

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$28.63

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRC
ACAD
Founded
1947
1993
Country
United States
United States
Employees
241
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.3B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
KRC
ACAD
Price
$37.38
$28.63
Analyst Decision
Hold
Buy
Analyst Count
12
22
Target Price
$37.36
$30.55
AVG Volume (30 Days)
1.3M
1.6M
Earning Date
04-27-2026
05-06-2026
Dividend Yield
6.57%
N/A
EPS Growth
31.07
69.12
EPS
N/A
0.20
Revenue
$1,112,667,000.00
$726,437,000.00
Revenue This Year
N/A
$18.80
Revenue Next Year
$2.13
$11.70
P/E Ratio
N/A
$144.00
Revenue Growth
N/A
40.45
52 Week Low
$27.36
$19.69
52 Week High
$45.03
$29.17

Technical Indicators

Market Signals
Indicator
KRC
ACAD
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
KRC
ACAD

About KRC Kilroy Realty Corporation

Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: